What question did this study set out to answer?

To evaluate the efficacy of ustekinumab, an antibody targeting the p40 subunit of interleukin-12 and interleukin-23, as intravenous induction and subcutaneous maintenance therapy for Crohn's disease.

November 16, 2016New England Journal of MedicineOpen Access

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy of ustekinumab, an antibody targeting the p40 subunit of interleukin-12 and interleukin-23, as intravenous induction and subcutaneous maintenance therapy for Crohn's disease.
Administered intravenous ustekinumab as induction therapy across two populations with moderately to severely active Crohn's disease.
Assessed subcutaneous ustekinumab regimens for ongoing maintenance therapy.
Evaluated clinical response and remission following intravenous induction therapy targeting interleukin-12 and interleukin-23 in active disease cohorts.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Clinical trial demonstrates the therapeutic potential of ustekinumab in moderately to severely active Crohn's disease, highlighting its value for induction and maintenance.

Cite This Study

Feagan et al. (2016) studied this question.

synapsesocial.com/papers/6a7d0b8a0e251d52761cc4e4 https://doi.org/10.1056/nejmoa1602773

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial demonstrates the therapeutic potential of ustekinumab in moderately to severely active Crohn's disease, highlighting its value for induction and maintenance.

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Key Points

Discussion

Implication

Cite This Study

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider